Nurix Therapeutics Engages Investors at Key Conferences
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company focused on developing targeted protein modulation therapies for cancer and inflammatory diseases. This September, the company will take part in several significant investor conferences.
Upcoming Conferences
Key executives from Nurix Therapeutics will be attending these important events:
Wells Fargo Healthcare Conference
On September 5, 2024, from 4:30 to 5:05 p.m. ET, Arthur T. Sands, M.D., Ph.D., the president and CEO, will engage in a fireside chat at the 2024 Wells Fargo Healthcare Conference. This conference provides a platform for industry leaders to discuss the latest advancements and challenges in healthcare.
H.C. Wainwright 26th Annual Global Investment Conference
The following week, on September 9, 2024, from 9:30 to 10:00 a.m. ET, Hans van Houte, the chief financial officer, will join another fireside chat during the H.C. Wainwright 26th Annual Global Investment Conference. This event is renowned for bringing together investors from around the world to connect with innovative companies.
Baird 2024 Global Healthcare Conference
Lastly, on September 10, 2024, from 9:50 to 10:20 a.m. ET, Jason Kantor, Ph.D., the chief business officer, will present at the Baird 2024 Global Healthcare Conference. This presentation will not be webcast, providing an exclusive opportunity for attendees to engage directly.
Webcast Access
Where applicable, the fireside chats will be available for live streaming. Interested investors can find these webcasts in the Investors section of the Nurix Therapeutics website under Events and Presentations. Additionally, an archive of the webcasts will be accessible for 30 days following each event, ensuring stakeholders can stay updated on the company's presentations.
The Vision of Nurix Therapeutics
Nurix Therapeutics is at the forefront of a new approach to treating cancer and inflammatory diseases. The company is dedicated to discovering, developing, and commercializing innovative small molecules and antibody therapies designed to modulate cellular protein levels, marking a significant advancement in treatment strategies.
Leveraging extensive expertise in E3 ligases, Nurix utilizes proprietary DNA-encoded libraries to enhance its research. The company has developed DELigase, an integrated discovery platform that identifies and advances new drug candidates targeting E3 ligases. These enzymes play a crucial role in modulating proteins within cells, highlighting Nurix's unique position in the pharmacological landscape.
In its ongoing research, Nurix aims to harness or inhibit the natural functions of E3 ligases within the ubiquitin-proteasome system. This focus allows for precise control over cellular protein levels, which is vital for therapeutic innovation.
Currently, Nurix's pipeline includes clinical-stage targeted protein degraders of Bruton’s tyrosine kinase, an essential protein in B-cell signaling, as well as inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase crucial for activating various immune cells, including T cells and NK cells. This diverse pipeline underscores Nurix's commitment to developing effective treatment options for patients facing serious health challenges.
Stay Informed About Nurix Therapeutics
For the latest updates and more information, visit the official website of Nurix Therapeutics. The site offers comprehensive details about the company's ongoing research, investor relations, and opportunities for new investor engagement.
Contact Information
For Investor Inquiries
Jason Kantor, Ph.D.
Nurix Therapeutics
Email: ir@nurixtx.com
Media Inquiries:
Aljanae Reynolds
Wheelhouse Life Science Advisors
Email: areynolds@wheelhouselsa.com
Frequently Asked Questions
What will be discussed at the upcoming conferences?
Executives from Nurix will discuss advancements in targeted protein modulation therapies and their potential impact on treating cancer and inflammatory diseases.
How can I access the webcasts?
The webcasts can be accessed through the Investors section of the Nurix Therapeutics website under Events and Presentations.
Who are the key executives participating in the conferences?
Arthur T. Sands, M.D., Ph.D., Hans van Houte, and Jason Kantor, Ph.D., will represent Nurix Therapeutics at the conferences.
What is the main focus of Nurix Therapeutics?
Nurix Therapeutics focuses on the discovery and development of small molecules and antibody therapies aimed at modulating protein levels to treat cancer and other diseases.
Where is Nurix Therapeutics located?
Nurix Therapeutics is headquartered in San Francisco, California, strategically positioned to engage with a thriving biopharmaceutical environment.